Payment overview · 2025
General Payments
$1,635.31
88 reported records · 21 companies
Healthcare provider profile · identity verified
Daniel R Barlow, MD
Allopathic & Osteopathic Physicians|Family Medicine · OPELIKA, AL · NPI 1457738338
Verified facts
What the public records show
CMS Open Payments records show Daniel R Barlow, MD received $1,635.31 in general payments during 2025 across 88 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.26 | 14.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $198.92 | 12.2% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.63 | 10.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.15 | 9.7% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.26 | 7.6% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $93.68 | 5.7% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $86.29 | 5.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $84.78 | 5.2% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $75.12 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.63 | 3.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.36 | 3.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $53.04 | 3.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.04 | 2.3% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $35.41 | 2.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.25 | 2.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $31.79 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.15 | 1.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $23.60 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.91 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 0.9% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $14.61 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,635.31 | 88 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $216.53 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $198.92 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $163.63 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $136.98 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.68 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.26 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $100.46 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $93.68 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $84.78 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $75.12 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.65 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.63 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.63 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.36 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.94 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $53.04 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $31.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $5.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 41 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 184 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
184 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 113 |
| Lisinopril | Lisinopril | 275 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 88 |
| Metformin Hcl | Metformin Hcl | 256 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 58 |
| Gabapentin | Gabapentin | 196 | 60 |
| Mounjaro | Tirzepatide | 184 | 32 |
| Losartan Potassium | Losartan Potassium | 183 | 65 |
| Omeprazole | Omeprazole | 180 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 47 |
| Trazodone Hcl | Trazodone Hcl | 130 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 41 |
| Simvastatin | Simvastatin | 97 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 13 |
| Carvedilol | Carvedilol | 85 | 30 |
| Bupropion Xl | Bupropion Hcl | 81 | 21 |
| Furosemide | Furosemide | 81 | 34 |
| Potassium Chloride | Potassium Chloride | 80 | 29 |
| Valsartan | Valsartan | 75 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 21 |
| Metformin Hcl Er | Metformin Hcl | 69 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 24 |
| Montelukast Sodium | Montelukast Sodium | 67 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 24 |
| Meloxicam | Meloxicam | 66 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 31 |
| Allopurinol | Allopurinol | 58 | 20 |
| Chlorthalidone | Chlorthalidone | 57 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 18 |
| Farxiga | Dapagliflozin Propanediol | 51 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Ozempic | Semaglutide | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 17 |
| Famotidine | Famotidine | 45 | 16 |
| Atenolol | Atenolol | 44 | 14 |
| Jardiance | Empagliflozin | 42 | 17 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Eliquis | Apixaban | 41 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 21 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Glimepiride | Glimepiride | 39 | 12 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 13 |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | 13 |
| Glipizide | Glipizide | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 12 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 11 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Linzess | Linaclotide | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Pregabalin | Pregabalin | 21 | 11 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,635.31 · 88 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Dyanavel XR, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INJECTAFER, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, Tymlos, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error